Technology | February 25, 2010

In-Vitro Diagnostics Detect Cardio-Toxic Biomarkers

At ACC 2010, Siemens Healthcare Diagnostics will highlight new clinical findings that demonstrate the importance and value of cardiac biomarker testing in the treatment and care of cancer patients exposed to potential cardio-toxic effects of chemotherapeutic agents. Cardiac biomarkers, such as troponin I and natriuretic peptides, are well-established for risk stratification of patients with acute coronary syndromes and heart failure. Studies have shown that these biomarkers may also be useful in the early detection of chemo-therapy induced cardio-toxicity.
 
ACC attendees are invited to visit the Siemens booth to review an educational presentation about cardiac biomarker testing in oncology patients and the future potential for early testing and intervention to help prevent adverse cardiac effects in oncology patients.
 
The company will explain its comprehensive cardiovascular and oncology product portfolio and the power of collaboration in cardiac care.
 

Related Content

American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center
News | Cardiac Diagnostics| October 20, 2017
The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation...
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Analytics 4 Life Raises $25 Million for AI-Backed Cardiac Imaging Technology
News | Advanced Visualization| October 20, 2017
October 20, 2017 — Digital health company Analytics 4 Life announced it has completed a $25 million Series B financin
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Role of Telomere Length in Cardiovascular Risk Assessment
Feature | Cardiac Diagnostics| October 19, 2017 | Nanette H. Bishopric, M.D., FACC, FAHA
A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratificatio
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
SunTech Medical Receives Third-Party Validation of CT40 BP Spot-Check Device
News | Blood Pressure Monitor| October 11, 2017
October 11, 2017 — The CT40 spot-check device from SunTech Medical has received third-party validation for...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Majority of High-Risk Stroke Patients Not Being Screened for Common Risk Factors
News | Stroke| September 28, 2017
September 28, 2017 — New research revealed that on average, more than 75 percent of people aged 65 and older worldwid
Overlay Init